Smartlens IOP monitoring


Blindness due to Glaucoma

What is Glaucoma?

A group of chronic and progressive eye diseases that permanently damage the optic nerve

Elevated eye pressure is the primary and only modifiable risk factor for Glaucoma, the leading cause of irreversible blindness worldwide 


Vision loss over time due to Glaucoma

of all patients are at the severe stage with a high risk of permanent

of mild and moderate patients can not be
well-controlled, and need treatment intensification every 12 months 

of mild and moderate patients are worsening in severity every
12 months 

of all patients
undergo surgeries
every 12 months

of all patients
permanently lose their vision
over time despite being treated
Why do people (still) go blind from glaucoma?, Susanne et al                                                                                    Clinical and Economic Burden of Glaucoma by Disease Severity, Shih et al

How is Glaucoma treated?

With prescription eye drops and surgical interventions that can temporarily lower eye pressure.
For every 1 mmHg reduction in eye pressure, the risk of optic nerve damage decreases by 11%

What is the biggest obstacle in Glaucoma management?

Eye pressure can only be measured for a few seconds giving a very limited understanding of the patient's condition and making Glaucoma a very difficult disease to diagnose and treat.
Smartlens' flagship product miLens is the first device capable of monitoring IOP as a non-invasive, electronics-free, and easy-to-use contact lens which will significantly improve Glaucoma management.

Smartlens owns a broad portfolio of clinical-stage technologies for IOP monitoring and smart therapies.

Smartlens' smart therapy enables fully personalized treatments by giving the right medication at the right time according to the patient’s IOP level.

Eye Pressure (IOP) Matters

More than 5 million people are currently being treated for Glaucoma in the U.S., while an estimated 50% of Glaucoma sufferers are undiagnosed ​​
Reducing eye pressure is the only known way of slowing down or stopping the progression of Glaucoma
 More than 140 million people are suffering from Glaucoma worldwide; and that number is expected to reach 300 million by 2040